Association between FGF10 expression and gland‑forming differentiation pattern in gastric adenocarcinoma: An immunohistochemical analysis

Fujibayashi,Seito; Kobayashi,Kazuhiro; Tomita,Hiroyuki; Watanabe,Daichi; Endo,Masahide; Yokoi,Ryoma; Matsumoto,Keita; Hayashi,Hirokatsu; Kuno,Masashi; Fukada,Masahiro; Yasufuku,Itaru; Sato,Yuta; Asai,Ryuichi; Tajima,Jesse Yu; Hara,Akira; Matsuhashi,Nobuhisa

doi:10.3892/ol.2025.15224

Association between FGF10 expression and gland‑forming differentiation pattern in gastric adenocarcinoma: An immunohistochemical analysis

Authors:
- Seito Fujibayashi
- Kazuhiro Kobayashi
- Hiroyuki Tomita
- Daichi Watanabe
- Masahide Endo
- Ryoma Yokoi
- Keita Matsumoto
- Hirokatsu Hayashi
- Masashi Kuno
- Masahiro Fukada
- Itaru Yasufuku
- Yuta Sato
- Ryuichi Asai
- Jesse Yu Tajima
- Akira Hara
- Nobuhisa Matsuhashi
View Affiliations

Affiliations: Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu 501‑1194, Japan, Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu 501‑1194, Japan, Department of Pharmacy, Gifu University Hospital, Gifu 501‑1194, Japan
Published online on: August 12, 2025 https://doi.org/10.3892/ol.2025.15224
Article Number: 479
Copyright: © Fujibayashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The histological classification of gastric adenocarcinoma influences its prognostic outcomes and therapeutic strategies. Although fibroblast growth factor (FGF)10 is important for gastric morphogenesis, its use as a molecular marker of gland‑forming differentiation pattern remains undefined. The present study examined 117 surgically resected gastric adenocarcinoma specimens using immunohistochemical analysis to evaluate the expression of FGF10 and FGF receptor 2 (FGFR2). Expression patterns in tumor cells and the surrounding stroma were assessed using a four‑tier scale. Associations between marker expression and histological differentiation were analyzed by multivariable ordinal logistic regression, adjusting for age, human epidermal growth factor receptor 2 and epidermal growth factor receptor status. Elevated FGF10 expression was significantly associated with well‑differentiated, gland‑forming histological subtypes, particularly in moderately differentiated tubular adenocarcinoma [adjusted odds ratio (OR) in tumor cells: 1.749, 95% confidence interval (CI) 1.231‑2.487, P=0.002; adjusted OR in stroma: 2.418, 95% CI 1.123‑5.206, P=0.024]. Conversely, FGFR2 expression showed no association with differentiation pattern (adjusted OR: 0.908, 95% CI 0.452‑1.824, P=0.788). Survival analysis revealed no significant relationship between FGF10 or FGFR2 expression level and overall patient survival [hazard ratio (HR) for FGF10 in tumor cells: 0.823, 95% CI 0.640‑1.057, P=0.127; HR for FGF10 in stroma: 0.675, 95% CI 0.385‑1.183, P=0.170; HR for FGFR2 in tumor cells: 1.080, 95% CI 0.559‑2.085, P=0.819]. FGF10 may thus be a promising molecular marker of gland‑forming differentiation pattern in gastric adenocarcinoma, offering valuable insights for refining its histopathological classification. These findings may contribute to the development of stratification biomarkers for personalized therapeutic approaches, particularly for the selection of molecular‑targeted therapies. The absence of an association with overall survival, however, highlights the need for further investigations into the underlying mechanisms and their broader clinical significance.

View Figures

View References

1	Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.PubMed/NCBI
2	Kakeji Y, Ishikawa T, Suzuki S, Akazawa K, Irino T, Miyashiro I, Ono H, Suzuki H, Tanabe S, Kadowaki S, et al: A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese gastric cancer association nationwide registry (2001–2013). Gastric Cancer. 25:1082–1093. 2022. View Article : Google Scholar : PubMed/NCBI
3	Cancer Genome Atlas Research Network, . Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
4	Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, et al: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021. View Article : Google Scholar : PubMed/NCBI
5	Sato Y, Okamoto K, Kawano Y, Kasai A, Kawaguchi T, Sagawa T, Sogabe M, Miyamoto H and Takayama T: Novel biomarkers of gastric cancer: Current research and future perspectives. J Clin Med. 12:46462023. View Article : Google Scholar : PubMed/NCBI
6	Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, et al: Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial. Lancet. 401:1655–1668. 2023. View Article : Google Scholar : PubMed/NCBI
7	Kawakami H and Okamoto I: MET-targeted therapy for gastric cancer: The importance of a biomarker-based strategy. Gastric Cancer. 19:687–695. 2016. View Article : Google Scholar : PubMed/NCBI
8	Shi T, Zhang Y, Wang Y, Song X, Wang H, Zhou X, Liang K, Luo Y, Che K, Wang X, et al: DKK1 promotes tumor immune evasion and impedes anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer. Cancer Immunol Res. 10:1506–1524. 2022. View Article : Google Scholar : PubMed/NCBI
9	Kim HS, Kim JH and Jang HJ: Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: A meta-analysis and systemic review. J Cancer. 10:2560–2567. 2019. View Article : Google Scholar : PubMed/NCBI
10	Gao Y, Zhang K, Xi H, Cai A, Wu X, Cui J, Li J, Qiao Z, Wei B and Chen L: Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: A meta-analysis. Oncotarget. 8:6330–6340. 2017. View Article : Google Scholar : PubMed/NCBI
11	Lee JS, Won HS, Sun S, Hong JH and Ko YH: Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis. Medicine (Baltimore). 97:e117692018. View Article : Google Scholar : PubMed/NCBI
12	Nakamura K, Sugano H and Takagi K: Carcinoma of the stomach in incipient phase: Its histogenesis and histological appearances. Gan. 59:251–258. 1968.PubMed/NCBI
13	Feng F, Liu J, Wang F, Zheng G, Wang Q, Liu S, Xu G, Guo M, Lian X and Zhang H: Prognostic value of differentiation status in gastric cancer. BMC Cancer. 18:8652018. View Article : Google Scholar : PubMed/NCBI
14	Zu H, Wang H, Li C and Xue Y: Clinicopathologic characteristics and prognostic value of various histological types in advanced gastric cancer. Int J Clin Exp Pathol. 7:5692–5700. 2014.PubMed/NCBI
15	Association JGC: Japanese Classification of Gastric Carcinoma 2017. 15th edition. Kanehara; Tokyo: 2017
16	Wang X, Deng J and Liang H: Well differentiated carcinoma with a poor prognosis: A retrospective analysis of papillary gastric adenocarcinoma. Surg Today. 51:1387–1396. 2021. View Article : Google Scholar : PubMed/NCBI
17	Li HZ, Zhu HT, Chen YY, Zheng RS, Jin GF, Du LB and Cheng XD: Five-year survival analysis of gastric cancer from population-based cancer registration data in Zhejiang province, China. Zhonghua Zhong Liu Za Zhi. 46:862–870. 2024.(In Chinese). PubMed/NCBI
18	Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, Nagahori Y, Takahashi M, Kito F and Shimada H: Clinicopathological properties of poorly-differentiated adenocarcinoma of the stomach: Comparison of solid- and non-solid-types. Anticancer Res. 26:639–646. 2006.PubMed/NCBI
19	Yasuda K, Adachi Y, Shiraishi N, Maeo S and Kitano S: Papillary adenocarcinoma of the stomach. Gastric Cancer. 3:33–38. 2000. View Article : Google Scholar : PubMed/NCBI
20	Shin HD, Bang KB, Kang SH, Moon HS, Sung JK, Jeong HY, Lee DK, Kim KB, Kim SM, Lee SW, et al: Clinical outcome of endoscopic submucosal dissection for papillary type early gastric cancer: A multicenter study. Gut Liver. 18:426–433. 2024. View Article : Google Scholar : PubMed/NCBI
21	Kim HS, Kim JH, Jang HJ, Han B and Zang DY: Pathological and prognostic impacts of FGFR2 overexpression in gastric cancer: A meta-analysis. J Cancer. 10:20–27. 2019. View Article : Google Scholar : PubMed/NCBI
22	Hur JY, Chao J, Kim K, Kim ST, Kim KM, Klempner SJ and Lee J: High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. Pathol Res Pract. 216:1528782020. View Article : Google Scholar : PubMed/NCBI
23	Ooki A and Yamaguchi K: The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration. Gastric Cancer. 24:1169–1183. 2021. View Article : Google Scholar : PubMed/NCBI
24	Yashiro M, Kuroda K, Masuda G, Okuno T, Miki Y, Yamamoto Y, Sera T, Sugimoto A, Kushiyama S, Nishimura S, et al: Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer. Sci Rep. 11:46982021. View Article : Google Scholar : PubMed/NCBI
25	Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C and Lutterbach B: FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 68:2340–2348. 2008. View Article : Google Scholar : PubMed/NCBI
26	Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, et al: Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): A randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 23:1430–1440. 2022. View Article : Google Scholar : PubMed/NCBI
27	Kang YK, Qin S, Lee KW, Oh SC, Kim IH, Kim JG, Li Y, Yan Z, Li J, Bai LY, et al: Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: Subgroup of FIGHT final analysis. Gastric Cancer. 27:1046–1057. 2024. View Article : Google Scholar : PubMed/NCBI
28	Wainberg ZA, Kang YK, Lee KW, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, et al: Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: Final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 27:558–570. 2024. View Article : Google Scholar : PubMed/NCBI
29	Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G and Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem. 271:15292–15297. 1996. View Article : Google Scholar : PubMed/NCBI
30	Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M and Ornitz DM: Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 281:15694–15700. 2006. View Article : Google Scholar : PubMed/NCBI
31	Ornitz DM and Itoh N: The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 4:215–266. 2015. View Article : Google Scholar : PubMed/NCBI
32	Nyeng P, Norgaard GA, Kobberup S and Jensen J: FGF10 signaling controls stomach morphogenesis. Dev Biol. 303:295–310. 2007. View Article : Google Scholar : PubMed/NCBI
33	Speer AL, Al Alam D, Sala FG, Ford HR, Bellusci S and Grikscheit TC: Fibroblast growth factor 10-fibroblast growth factor receptor 2b mediated signaling is not required for adult glandular stomach homeostasis. PLoS One. 7:e491272012. View Article : Google Scholar : PubMed/NCBI
34	Ooi A, Oyama T, Nakamura R, Tajiri R, Ikeda H, Fushida S, Nakamura H and Dobashi Y: Semi-comprehensive analysis of gene amplification in gastric cancers using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization. Mod Pathol. 28:861–871. 2015. View Article : Google Scholar : PubMed/NCBI
35	Sun Q, Lin P, Zhang J, Li X, Yang L, Huang J, Zhou Z, Liu P and Liu N: Expression of fibroblast growth factor 10 is correlated with poor prognosis in gastric adenocarcinoma. Tohoku J Exp Med. 236:311–318. 2015. View Article : Google Scholar : PubMed/NCBI
36	Board WCoTE: Digestive System Tumours. International Agency for Research on Cancer; Lyon: 2019
37	Brierley JD, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours. 8th edition. Wiley-Blackwell; Hoboken: pp. 63–69. 2017
38	Altman DG, McShane LM, Sauerbrei W and Taube SE: Reporting recommendations for tumor marker prognostic studies (REMARK): Explanation and elaboration. PLoS Med. 9:e10012162012. View Article : Google Scholar : PubMed/NCBI
39	Röcken C: Predictive biomarkers in gastric cancer. J Cancer Res Clin Oncol. 149:467–481. 2023. View Article : Google Scholar : PubMed/NCBI
40	Watson J and Francavilla C: Regulation of FGF10 signaling in development and disease. Front Genet. 9:5002018. View Article : Google Scholar : PubMed/NCBI
41	Sankoda N, Tanabe W, Tanaka A, Shibata H, Woltjen K, Chiba T, Haga H, Sakai Y, Mandai M, Yamamoto T, et al: Epithelial expression of Gata4 and Sox2 regulates specification of the squamous-columnar junction via MAPK/ERK signaling in mice. Nat Commun. 12:5602021. View Article : Google Scholar : PubMed/NCBI
42	Abolhassani A, Riazi GH, Azizi E, Amanpour S, Muhammadnejad S, Haddadi M, Zekri A and Shirkoohi R: FGF10: Type III epithelial mesenchymal transition and invasion in breast cancer cell lines. J Cancer. 5:537–547. 2014. View Article : Google Scholar : PubMed/NCBI
43	Lv YQ, Wu J, Li XK, Zhang JS and Bellusci S: Role of FGF10/FGFR2b signaling in mouse digestive tract development, repair and regeneration following injury. Front Cell Dev Biol. 7:3262019. View Article : Google Scholar : PubMed/NCBI
44	Clayton NS and Grose RP: Emerging roles of fibroblast growth factor 10 in cancer. Front Genet. 9:4992018. View Article : Google Scholar : PubMed/NCBI
45	Ndlovu R, Deng LC, Wu J, Li XK and Zhang JS: Fibroblast growth factor 10 in pancreas development and pancreatic cancer. Front Genet. 9:4822018. View Article : Google Scholar : PubMed/NCBI
46	Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA and Witte ON: Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell. 12:572–585. 2007. View Article : Google Scholar : PubMed/NCBI
47	Matsuike A, Ishiwata T, Watanabe M and Asano G: Expression of fibroblast growth factor (FGF)-10 in human colorectal adenocarcinoma cells. J Nippon Med Sch. 68:397–404. 2001. View Article : Google Scholar : PubMed/NCBI